Blog
What Is AOD-9604? hGH Fragment 176-191, Research Evidence and Analytical Identity
Updated October 2026 • 7 min read • For qualified laboratory research education
AOD-9604 is a defined synthetic peptide related to a C-terminal region of human growth hormone, not full-length hGH.
Preclinical, clinical-development and regulatory evidence should be kept in separate evidence tiers.
Sequence identity still needs lot-specific analytical verification in a purchased research material.
AOD-9604 is often described online with shorthand phrases such as “hGH fragment 176-191,” but that description can be misleading if it makes the compound sound like full-length human growth hormone. AOD-9604 is a defined synthetic peptide with 16 amino acids and its own chemical identity.
PubChem lists the sequence as YLRIVQCRSVEGSCGF and describes AOD-9604 as a synthetic analog of the lipolytic domain of human growth hormone. The research history includes early animal metabolism work, clinical development efforts and later regulatory review of the substance for compounding.
What is AOD-9604 chemically?
AOD-9604 is a 16-residue peptide derived from a C-terminal region of human growth hormone, with an additional tyrosine at the N-terminus in the defined research molecule. PubChem lists molecular formula C78H123N23O23S2 and a molecular weight of approximately 1815.1 g/mol for the reference species.
Those registry values are identity anchors. They are not a substitute for testing an actual lot. Salt form, counterions, residual water and formulation can affect the mass composition of a vial without changing the underlying sequence identity.
Is AOD-9604 the same as human growth hormone?
No. Full-length human growth hormone is a much larger protein. AOD-9604 represents a small derived region engineered as a separate investigational molecule. That distinction matters because a fragment can preserve, lose or alter biological properties relative to the parent protein.
Researchers should therefore avoid transferring every biological effect associated with hGH to AOD-9604. The correct evidence base is the one generated with AOD-9604 itself.
What did the early research investigate?
Early preclinical studies examined metabolic effects in animal models. A 2001 paper reported observations in obese Zucker rats and framed the peptide as a synthetic analog of an hGH lipolytic domain. Those findings helped motivate clinical development, but animal data and human therapeutic efficacy are different evidence levels.
Why the human evidence needs careful interpretation
AOD-9604 progressed far enough to generate human development and safety information, but the clinical program did not establish the type of efficacy that internet marketing often implies. FDA’s 2024 review materials for the Pharmacy Compounding Advisory Committee emphasized insufficient evidence of effectiveness for obesity and unresolved characterization and safety questions when evaluating AOD-9604-related bulk drug substances.
That regulatory history is useful because it demonstrates why a mechanistically interesting peptide can still have a weak or incomplete clinical evidence base.
What a research buyer should verify
| Check | Why it matters |
|---|---|
| Name / sequence | Separates AOD-9604 from generic “hGH fragment” marketing |
| Salt / form | Free base and salt descriptions should not be silently mixed |
| Mass-spectrometry identity | Supports alignment with the expected molecular species |
| HPLC purity | Describes chromatographic composition under the stated method |
| Lot mapping | Connects the vial to the exact analytical report |
For a detailed explanation of those methods, see HPLC vs LC-MS for Research Peptides and Peptide Purity vs Peptide Content.
Confirm the fragment identity before comparing AOD-9604 studies
AOD-9604 is frequently described in shorthand as an hGH fragment, but that description should lead to more precision, not less. A buyer should verify that the product listing identifies the intended fragment, record the supplied form and presentation, and keep the lot documentation with the experiment. That prevents data from being attributed broadly to “growth hormone” when the actual research material is a specific peptide fragment.
For Nerolta, this page can answer a sourcing question without making outcome claims. Readers who arrive through “what is AOD-9604?” already need identity clarification; the next useful action is to inspect the current AOD-9604 research listing and compare the product details with the chemical and evidence context they just learned.
- Record AOD-9604 as the specific research compound rather than collapsing it into full-length hGH terminology.
- Verify the current product presentation and batch information before the material enters the laboratory inventory.
- Use the analytical documentation to support identity/purity questions and the literature to support scientific context—do not substitute one for the other.
Why this matters for a laboratory buyer: the research question and the procurement decision should connect cleanly. A product page should make it easy to verify identity, presentation, current price and available batch information without relying on exaggerated outcome claims. That transparency supports a faster, more defensible sourcing decision.
Before you order: make the product page part of the research record
Open the exact Nerolta listing and compare the compound name, current presentation, supplied form, storage wording, price and any available batch documentation against your laboratory SOP before purchasing. If an older article, cached result or search snippet differs from the live product page, use the live listing for the current commercial offering and the cited scientific literature for research context.
After purchase, archive the order confirmation, lot identifier and supporting documentation with the experiment record. That creates a cleaner chain from literature review to procurement and makes reorders, troubleshooting and cross-lot comparisons easier without turning marketing copy into scientific evidence.
Check the current AOD-9604 research listing
Review Nerolta’s AOD-9604 presentation, price and research-use information before selecting material for a qualified laboratory project.
View AOD-9604 research compoundExplore the full catalog
Frequently asked research questions
Is AOD-9604 full-length growth hormone?
No. It is a short synthetic peptide derived from a C-terminal region associated with hGH research.
Is AOD-9604 a GLP-1 compound?
No. It is chemically and pharmacologically distinct from GLP-1 receptor agonists and from triple-agonist molecules such as retatrutide.
Does a high HPLC percentage prove the vial contains the correct peptide?
No. HPLC purity and molecular identity are separate analytical questions. Mass spectrometry or another orthogonal identity method strengthens verification.
Why the “176-191” label can be confusing
Researchers will encounter AOD-9604 described as hGH 176-191 and also as a fragment corresponding to residues 177-191 with an added N-terminal tyrosine. The apparent mismatch comes from how the engineered sequence is counted and described relative to the native growth-hormone sequence. The safest approach is to anchor identity to the explicit amino-acid sequence and registry record rather than relying on residue shorthand alone.
This is exactly the kind of naming issue that can create false equivalence between products. Two vendors can use the same marketing phrase while documenting different salt forms or even different sequence descriptions. Sequence-level identity, lot documentation and mass data are stronger anchors than a nickname.
What the AOD-9604 story teaches about evidence quality
AOD-9604 is a useful case study because the scientific narrative changed as evidence accumulated. Early animal data created a plausible metabolic research story. Development then moved into humans, where the therapeutic case did not mature into an approved obesity medicine. Later regulatory review focused not only on biological plausibility but also on characterization, immunogenicity and the amount of reliable safety and efficacy evidence available.
That progression is valuable for researchers: a compound can have a coherent mechanism, positive animal results and genuine scientific interest without satisfying the much higher bar required for a validated human therapy. SEO content should preserve that distinction rather than repeating the most favorable early-stage finding as if it were the final conclusion.
Common AOD-9604 search terms that are not interchangeable
- AOD-9604: the defined research peptide.
- hGH fragment 176-191: a common shorthand that should be checked against the actual sequence.
- growth hormone: the full-length protein, not AOD-9604.
- fat-loss peptide: a marketing phrase, not a chemical identity.
- AOD-9604 acetate: a salt/form description that should be distinguished from free-base references.
For search users and laboratory buyers alike, the chemically precise term should lead the page and the aliases should be explained rather than treated as synonyms without qualification.
Explore AOD-9604 for laboratory research
Review the Nerolta Labs AOD-9604 research listing, product presentation and available batch information.
References & further reading
- PubChem: AOD-9604, CID 71300630
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
- FDA PCAC briefing: AOD-9604-related bulk drug substances
